[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349814-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349814-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","validation-of-a-clinical-and-polygenic-risk-prediction-model-for-ovarian-cancer-in-the-nurses-health-study","Validation of a Clinical and Polygenic Risk Prediction Model for Ovarian Cancer in the Nurses’ Health Study","","Ovarian cancer remains the leading cause of death among gynecologic cancers due to late diagnosis, motivating improved risk stratification for targeted prevention. A refined polygenic risk–integrated clinical model is cross-validated in nested case–control data from the Nurses’ Health Study and compared with a clinical risk score and a polygenic risk score model. Model performance is reported using odds ratios per standard deviation and AUC values, while screening history is reviewed for stage-shifting and unclear mortality benefit. The study supports validating combined clinical and polygenic prediction to guide preventive interventions and surveillance intensity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/validation-of-a-clinical-and-polygenic-risk-prediction-model-for-ovarian-cancer-in-the-nurses-health-study/349814/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/validation-of-a-clinical-and-polygenic-risk-prediction-model-for-ovarian-cancer-in-the-nurses-health-study/349814.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of validating the refined risk model in this study?","Question",{"text":63,"@type":64},"The study validates the predictive performance of a combined clinical and polygenic model for ovarian cancer to support more accurate risk assessment and better preventive decision-making.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the refined risk model compare with other risk approaches?",{"text":68,"@type":64},"The refined risk model is compared against a clinical risk score model and a polygenic risk score model, with performance summarized using odds ratios per standard deviation and AUC values.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is polygenic risk included alongside clinical factors?",{"text":72,"@type":64},"High-risk pathogenic variants are rare and do not account for the majority of ovarian cancer cases, so incorporating polygenic risk is used to improve risk stratification beyond family history and single-gene carriers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349814,1790709267,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Validation of a Clinical and Polygenic Risk Prediction Model for Ovarian Cancer in the Nurses’ Health Study  \nKrishna Patel1, Gillian S. Dite2, Erika L. Spaeth2, and Bernard A. Rosner1  \n|  |  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 􀀶 |  | Ovarian cancer is the leading cause of death among gynecologic cancers because of its late diagnosis, but risk stratification for targeted prevention can improve outcomes. To identify women at risk of ovarian cancer, pathogenic variant testing is used, especially for those with a family history of the disease. However, high-risk genetic variants are rare, accounting for \u003C20% of ovarian cancer cases overall. More recently, clinical models that help identify ovarian cancer cases incorporate polygenic risk for improved risk stratification. Herein, we cross-validate a polygenic risk–integrated clinical model called the refined risk model in a nested case–control population from the Nurses’ Health Study. The refined risk model is compared with a clinical risk score and polygenic risk score model, respectively. The ORs per SD were 1.26 (1.01, 1.48), 1.13 (0.96, 1.33), and 1.22 (1.04, 1.43) with corresponding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | AUCs of 0.56 (0 .51, 0.61), 0.54 (0 .49, 0.59), and 0.55 (0 .50, 0.60) for the refined risk, clinical risk, and polygenic risk models, respectively. Population screening has been assessed over the years, and although stage-shifting in the screened population has occurred, the mortality benefit was not evident. However, as treatments for ovarian cancer improve, the benefits of a risk-stratified approach to screening are expected to grow.\u003Cbr>Prevention Relevance: In this study, we have validated the predictive performance of a combined clinical and polygenic model for ovarian cancer. Accurate risk assessment enables more efficient allocation of preventive interventions, including intensified surveillance and consideration of risk-reducing salpingo-oophorectomy among women at elevated risk. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nIn clinical settings, a family history of ovarian cancer or being a carrier of a pathogenic or likely pathogenic germline mutation in an ovarian cancer predisposition gene is used to identify women at high risk of the disease. Although no standard threshold exists for risk-reducing salpingo-oophorectomy, the National Comprehensive Cancer Network (NCCN) not only recommends this targeted prevention option at a threshold of 10% lifetime risk but also recommends its consideration for women with 3% to 5% lifetime risk (i. e., PALB2 carriers) . Women who have not completed childbearing or who do not want to undergo surgery may discuss surveillance using transvaginal ultrasound or screening for cancer antigen 125 with the support of the risk of ovarian cancer algorithm; however, there is no known survival benefit despite evidence of stage shift occurri","cbCaipnFDIhmWmsO","https://ap.wps.com/l/cbCaipnFDIhmWmsO","pdf",3255351,"English","# Introduction\n## Risk assessment and prevention options\n## Genetic carriers and population risk\n## Familial aggregation and explained variance","[{\"question\":\"What is the purpose of validating the refined risk model in this study?\",\"answer\":\"The study validates the predictive performance of a combined clinical and polygenic model for ovarian cancer to support more accurate risk assessment and better preventive decision-making.\"},{\"question\":\"How does the refined risk model compare with other risk approaches?\",\"answer\":\"The refined risk model is compared against a clinical risk score model and a polygenic risk score model, with performance summarized using odds ratios per standard deviation and AUC values.\"},{\"question\":\"Why is polygenic risk included alongside clinical factors?\",\"answer\":\"High-risk pathogenic variants are rare and do not account for the majority of ovarian cancer cases, so incorporating polygenic risk is used to improve risk stratification beyond family history and single-gene carriers.\"}]","Validation of a Clinical and Polygenic Risk Prediction Model for Ovarian Cancer in the Nurses’ Health Study | PDF",1790085725,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cdb1ca5cf5c5e6ecd8b4ea7a97bce87.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60dd021f15b1076c753dd4703bd5229e.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e30d55831685eaa718fa550da731a022.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/131de4d81637671da944401288d41f9a.webp",980,1311]